Skip to main content

Neumann Mark's Form 4 filing

Intra-Cellular Therapies, Inc. (ITCI) · filed Feb 27, 2024

Accession no.
0000950170-24-021564
Filed
Feb 27, 2024
Trade date
Feb 23-26, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $554.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Neumann MarkCIK 0001756211Officer (EVP, Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 23, 2024Common StockMOption exerciseAcquired+7,907––37,607Direct
Feb 26, 2024Common StockSSaleDisposed−200$68.03−$13,60637,407Direct
Feb 26, 2024Common StockSSaleDisposed−4,059$69.56−$282,344.0433,348Direct
Feb 26, 2024Common StockSSaleDisposed−2,341$70.70−$165,508.731,007Direct
Feb 26, 2024Common StockSSaleDisposed−1,307$71.18−$93,032.2629,700Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 23, 2024Common StockMOption exerciseDisposed−7,907$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)